AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28295445 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 EFA supplements (1000 mg/day eicosapentaenoic acid + 500 mg/day docosahexaenoic acid)
Number of subjects: 12
Study 28295445 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil 1500 mg/day)
Number of subjects: 12
Study 25271015 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol esters (4 g) in a high-fat shake
Number of subjects: 18
Study 25271015 — intervention group
Group type: COMPARATOR
Intervention: Control shake without plant stanol esters
Number of subjects: 18
Study 25271015 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol-enriched margarine (3 g/day)
Number of subjects: 18
Study 25271015 — intervention group
Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 18
Study 23496897 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention including usual care plus psychologist, occupational physician, ergonomist, case manager, and physiotherapist as RTW-coordinator.
Number of subjects: 770
Study 23496897 — intervention group
Group type: COMPARATOR
Intervention: Usual care (physiotherapist, chiropractor, rheumatologist, social worker).
Number of subjects: 770
Study 21464376 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care restructuring and motivational interviewing by clinicians with educational modules targeting television viewing and fast food and sugar-sweetened beverage intake.
Number of subjects: 475
Study 18337741 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity administered by the infant's mother (MOM)
Number of subjects: 33
Study 18337741 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity administered by a trained therapist (OT)
Number of subjects: 33
Study 18337741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical activity)
Number of subjects: 33
Study 17065618 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg once daily
Number of subjects: 11
Study 17065618 — intervention group
Group type: COMPARATOR
Intervention: Daptomycin 6 mg/kg once daily plus Gentamicin 1 mg/kg every 8 h
Number of subjects: 11
Study 14998110 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment (Beh)
Number of subjects: 0
Study 14998110 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management (MedMgt)
Number of subjects: 0
Study 14998110 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medication and behavioral treatment (Comb)
Number of subjects: 0
Study 14998110 — intervention group
Group type: COMPARATOR
Intervention: Community care (CC)
Number of subjects: 0
Study 14998110 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 14998110 — intervention group
Group type: EXPERIMENTAL
Intervention: Main outcome measure (composite of parent- and teacher-rated ADHD and ODD symptoms)
Number of subjects: 0
Study 11335792 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA 10 mg/kg
Number of subjects: 6
Study 11335792 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA 5 mg/kg
Number of subjects: 6
Study 9330586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (15 mg/kg body weight/day)
Number of subjects: 84
Study 9330586 — intervention group
Group type: COMPARATOR
Intervention: Nicotinamide (25 mg/kg body weight/day)
Number of subjects: 84
Study 7883133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy (SK or rtPA)
Number of subjects: 69812
Study 7883133 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 69812
Study 3066675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 181
Study 29113956 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus mailed hrHPV self-screening kits
Number of subjects: 1000
Study 29113956 — intervention group
Group type: COMPARATOR
Intervention: Usual care (annual patient reminders and ad hoc outreach by clinics)
Number of subjects: 1000
Study 28595523 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-enriched white lighting (17000 K ≅ 900 lux)
Number of subjects: 80
Study 28595523 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-enriched white lighting (17000 K)
Number of subjects: 80
Study 28595523 — intervention group
Group type: COMPARATOR
Intervention: Control white lighting (4000 K ≅ 200 lux)
Number of subjects: 80
Study 25804335 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter BIPFoley‐Bactiguard® (CBF)
Number of subjects: 116
Study 25804335 — intervention group
Group type: COMPARATOR
Intervention: Catheter Foley
Number of subjects: 116
Study 23849714 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 268
Study 23849714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 21431354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass granules (BG)
Number of subjects: 25
Study 21431354 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone (AB)
Number of subjects: 25
Study 18307280 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID treatment (indomethacin or celebrex) for three days preoperatively
Number of subjects: 100
Study 18307280 — intervention group
Group type: COMPARATOR
Intervention: Control (esomeprazole)
Number of subjects: 100
Study 16572861 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 44
Study 16572861 — intervention group
Group type: COMPARATOR
Intervention: Sharp dissection
Number of subjects: 44
Study 14763034 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour exchange
Number of subjects: 9
Study 14763034 — intervention group
Group type: COMPARATOR
Intervention: 8-hour exchange
Number of subjects: 9
Study 10716466 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1,200 mg/day)
Number of subjects: 23
Study 10716466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA) (mean dose 2,250 mg/day)
Number of subjects: 23
Study 10716466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of gemfibrozil plus NA
Number of subjects: 23
Study 10716466 — intervention group
Group type: COMPARATOR
Intervention: Baseline/Washout
Number of subjects: 23
Study 10716466 — intervention group
Group type: COMPARATOR
Intervention: Nicotinic acid vs. gemfibrozil
Number of subjects: 23
Study 10716466 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy vs. gemfibrozil alone
Number of subjects: 23
Study 10716466 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy vs. NA alone
Number of subjects: 23
Study 10716466 — intervention group
Group type: EXPERIMENTAL
Intervention: Other lipid parameters
Number of subjects: 23
Study 9184390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed minidose warfarin 1.25 mg/day
Number of subjects: 100
Study 9184390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined minidose warfarin (1.25 mg/day) and aspirin (300 mg/day)
Number of subjects: 100
Study 9184390 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose adjusted warfarin (INR 2.0-3.0)
Number of subjects: 100
Study 9184390 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day
Number of subjects: 100
Study 8473474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg)
Number of subjects: 46
Study 8473474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 3816922 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg p.o.
Number of subjects: 12
Study 29366724 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise program
Number of subjects: 45
Study 29366724 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 45
Study 29300273 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-min CPR training session
Number of subjects: 424
Study 29300273 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 424
Study 27653383 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based therapeutic education system (TES) for 12 weeks
Number of subjects: 507
Study 27653383 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based therapeutic education system (TES)
Number of subjects: 507
Study 27653383 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 507
Study 25639140 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-source food supplement 5 days per week from marriage to term (approximately 13 months)
Number of subjects: 0
Study 25639140 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-source food supplement 5 days per week from 16 weeks of gestation to term (approximately 5 months)
Number of subjects: 0
Study 25639140 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care without supplemental feeding
Number of subjects: 0
Study 23686277 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ileoanal pouch procedure (LAP)
Number of subjects: 42
Study 23686277 — intervention group
Group type: COMPARATOR
Intervention: Conventional ileoanal pouch procedure (CON)
Number of subjects: 42
Study 23686277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LAP and CON
Number of subjects: 42
Study 20570472 — intervention group
Group type: EXPERIMENTAL
Intervention: TrapEase IVC filter
Number of subjects: 156
Study 20570472 — intervention group
Group type: COMPARATOR
Intervention: Greenfield IVC filter
Number of subjects: 156
Study 18160963 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV‐AS04
Number of subjects: 57
Study 18160963 — intervention group
Group type: COMPARATOR
Intervention: Standard hepatitis B vaccine (double doses)
Number of subjects: 57
Study 18160963 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster doses of HBV‐AS04
Number of subjects: 57
Study 15681945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP)
Number of subjects: 700
Study 15681945 — intervention group
Group type: COMPARATOR
Intervention: Sham cricoid pressure (sham CP)
Number of subjects: 700
Study 12357713 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry (AR)
Number of subjects: 10
Study 10362454 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO (milk protein hydrolysate supplemented drink)
Number of subjects: 0
Study 10362454 — intervention group
Group type: COMPARATOR
Intervention: CHO (same drink without protein)
Number of subjects: 0
Study 7723156 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to promote adherence to a diet providing 28% of energy from total fat, less than 8% from saturated fat, up to 9% from polyunsaturated fat, and less than 75 mg/4200 kJ (1000 kcal) per day of cholesterol (not to exceed 150 mg/d)
Number of subjects: 663
Study 7723156 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 663
Study 7723156 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 663
Study 2123987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography during and after radical radiotherapy
Number of subjects: 50
Study 2123987 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning during and after radical radiotherapy
Number of subjects: 50
Study 2123987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography and CT scanning for initial tumor area measurements
Number of subjects: 50
Study 2123987 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of tumor calcification during and after radiotherapy
Number of subjects: 50
Study 2123987 — intervention group
Group type: EXPERIMENTAL
Intervention: CT number measurement of the tumor after radiotherapy
Number of subjects: 50
Study 2123987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoscopy within 6 months of the start of radiotherapy
Number of subjects: 50
Study 7362505 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% phenylephrine
Number of subjects: 150
Study 7362505 — intervention group
Group type: COMPARATOR
Intervention: 1% tropicamide
Number of subjects: 150
Study 31968573 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term group-based exercise (SGB) for 6 weeks followed by 18 weeks of home-based exercise
Number of subjects: 55
Study 31968573 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term group-based exercise (LGB) for 12 weeks followed by 18 weeks of home-based exercise
Number of subjects: 55
Study 31342138 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.2 g/d of elemental calcium in the form of calcium carbonate)
Number of subjects: 1368
Study 28779963 — intervention group
Group type: COMPARATOR
Intervention: 40 Gy whole-breast radiotherapy (control)
Number of subjects: 2018
Study 28779963 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 Gy whole-breast radiotherapy and 40 Gy to the partial breast (reduced-dose group)
Number of subjects: 2018
Study 28779963 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy to the partial breast only (partial-breast group)
Number of subjects: 2018
Study 28779963 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose and partial-breast radiotherapy
Number of subjects: 2018
Study 26116717 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical monitoring
Number of subjects: 401
Study 26116717 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient monitoring
Number of subjects: 401
Study 25138182 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (DEB)
Number of subjects: 50
Study 25138182 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 50
Study 23033005 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (cape) treatment with HFSR
Number of subjects: 374
Study 23033005 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (cape) treatment without HFSR
Number of subjects: 374
Study 19796562 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E gel (D-alpha-tocopheryl acetate) applied twice a week
Number of subjects: 27
Study 19796562 — intervention group
Group type: COMPARATOR
Intervention: Standard ulcer care protocol only (Control)
Number of subjects: 27
Study 18079221 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg/d for 4 weeks)
Number of subjects: 14
Study 18079221 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast withdrawal
Number of subjects: 14
Study 18079221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10745058 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (250 mg testosterone enanthate)
Number of subjects: 30
Study 10745058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8942440 — intervention group
Group type: EXPERIMENTAL
Intervention: Early versus deferred antiretroviral treatment
Number of subjects: 0
Study 8942440 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical models of HIV epidemic
Number of subjects: 0
Study 8942440 — intervention group
Group type: COMPARATOR
Intervention: Mathematical modeling approach
Number of subjects: 0
Study 1561479 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 UI/day of salmon calcitonin (CT) by nasal spray
Number of subjects: 20
Study 1561479 — intervention group
Group type: COMPARATOR
Intervention: Placebo by nasal spray
Number of subjects: 20
Study 2996327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic irradiation of the brain (3,000 rad in 10 fractions)
Number of subjects: 104
Study 2996327 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic irradiation of the brain
Number of subjects: 104
Study 30880952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health workers (LHWs) intervention
Number of subjects: 110
Study 29478011 — intervention group
Group type: EXPERIMENTAL
Intervention: SecurAcath
Number of subjects: 105
Study 29478011 — intervention group
Group type: COMPARATOR
Intervention: StatLock
Number of subjects: 105
Study 27364372 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) group: initial arthrocentesis plus PRP injection and then four consecutive PRP injections.
Number of subjects: 31
Study 27364372 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) group: one session of arthrocentesis plus HA injection.
Number of subjects: 31
Study 24246589 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated care
Number of subjects: 60
Study 24246589 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 22460259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopic holmium laser lithotripsy under epidural or lumbar anesthesia
Number of subjects: 50
Study 22460259 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ureterolithotomy under general anesthesia
Number of subjects: 50
Study 20650471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline 2.5 mg
Number of subjects: 16
Study 20650471 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% basal rate insulin reduction for 6 hours
Number of subjects: 16
Study 20650471 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 16
Study 18757014 — intervention group
Group type: EXPERIMENTAL
Intervention: Drained serums prepared by an infusion system and a three-way valve
Number of subjects: 672
Study 18757014 — intervention group
Group type: COMPARATOR
Intervention: Drained serums
Number of subjects: 672
Study 15914526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone (150 mg IM biweekly)
Number of subjects: 0
Study 15914526 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (6 mg SC daily)
Number of subjects: 0
Study 15914526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12769161 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria at baseline
Number of subjects: 0
Study 12769161 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of microalbuminuria
Number of subjects: 0
Study 12769161 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors and low-dose diuretics
Number of subjects: 0
Study 11379860 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% amino acid dialysis solution (AADS)
Number of subjects: 8
Study 11379860 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis solutions (control)
Number of subjects: 8
Study 15321377 — intervention group
Group type: EXPERIMENTAL
Intervention: SM: 0.1 mg
Number of subjects: 48
Study 15321377 — intervention group
Group type: EXPERIMENTAL
Intervention: SM: 0.2 mg
Number of subjects: 48
Study 15321377 — intervention group
Group type: EXPERIMENTAL
Intervention: SM: 0.1 mg plus K 60 mg i.v. one hour after spinal injection, and 30 mg i.v. every 6 h for three doses
Number of subjects: 48
Study 15321377 — intervention group
Group type: EXPERIMENTAL
Intervention: K dosed as previously described (but no SM)
Number of subjects: 48
Study 15321377 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 48
Study 1757615 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol propionate cream
Number of subjects: 111
Study 1757615 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 111
Study 29863433 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-component module including perspective taking, education, and direct contact with gay and lesbian persons
Number of subjects: 115
Study 29863433 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 115
Study 30473019 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Circuit Training (HICT)
Number of subjects: 22
Study 30473019 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 22
Study 30473019 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 22
Study 26988231 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature stable carbetocin (100 μg intramuscular)
Number of subjects: 30000
Study 26988231 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (10 IU intramuscular)
Number of subjects: 30000
Study 24359507 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day with cognitive-behavior and motivation-enhancement therapy
Number of subjects: 52
Study 24359507 — intervention group
Group type: COMPARATOR
Intervention: Placebo with cognitive-behavior and motivation-enhancement therapy
Number of subjects: 52
Study 22480131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (100-1600 mcg)
Number of subjects: 130
Study 22480131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 20574411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal gel (0.05%)
Number of subjects: 36
Study 20574411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel 4789 (Dapivirine vaginal gel)
Number of subjects: 36
Study 20574411 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl cellulose-based universal placebo gel
Number of subjects: 36
Study 18853557 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who saw faces with features in the high position during the memory task
Number of subjects: 0
Study 18853557 — intervention group
Group type: COMPARATOR
Intervention: Participants who saw faces with features in the low position during the memory task
Number of subjects: 0
Study 18853557 — intervention group
Group type: COMPARATOR
Intervention: Participants who saw faces with features in the average position during the memory task
Number of subjects: 0
Study 15868442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in patients with moderate cyclin D1 expression
Number of subjects: 230
Study 15868442 — intervention group
Group type: EXPERIMENTAL
Intervention: ErbB2 overexpression in patients with cyclin D1 overexpression
Number of subjects: 230
Study 15868442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D1 expression levels (weak, moderate, strong)
Number of subjects: 230
Study 15868442 — intervention group
Group type: EXPERIMENTAL
Intervention: ErbB2 overexpression
Number of subjects: 230
Study 12902960 — intervention group
Group type: EXPERIMENTAL
Intervention: SB Charité artificial disc replacement
Number of subjects: 60
Study 12902960 — intervention group
Group type: COMPARATOR
Intervention: BAK anterior interbody fusion
Number of subjects: 60
Study 10098360 — intervention group
Group type: EXPERIMENTAL
Intervention: vincristine 0.01%
Number of subjects: 20
Study 10098360 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 20
Study 8689817 — intervention group
Group type: EXPERIMENTAL
Intervention: R(+)‐terodiline hydrochloride (100 mg)
Number of subjects: 9